Imagine a world where life-saving drugs are developed in a fraction of the time it currently takes, thanks to cutting-edge technology that can design proteins with pinpoint accuracy to target diseases. Artificial intelligence is making this vision a reality by transforming the field of protein
The landscape of medical treatment has been profoundly transformed by biologics—complex therapies like monoclonal antibodies, recombinant proteins, and nucleic acid-based solutions that target diseases with remarkable precision. Despite their groundbreaking impact, a significant challenge persists:
Diving into the gritty world of hardcore and metal, I’m thrilled to sit down with Billy Graziadei, the powerhouse frontman of Biohazard, a band that’s been a cornerstone of New York hardcore for decades. With their latest track “Death of Me” already making waves and a new album, Divided We Fall ,
Imagine a world where artificial intelligence, a tool celebrated for its potential to revolutionize biotechnology, becomes a double-edged sword capable of designing harmful biological materials with alarming precision, raising urgent concerns about biosecurity. This unsettling reality has come to
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research, development, and cutting-edge technology in the industry. Today, we’re diving into an exciting partnership that promises to revolutionize traceability in clinical consumables, focusing on
In a landscape where rare diseases often struggle for attention and innovation, cutaneous T-cell lymphoma (CTCL)—encompassing mycosis fungoides (MF) and Sézary syndrome (SS)—stands as a stark reminder of unmet medical needs. With only a small fraction of cancer cases attributed to these conditions,
